Hematopoietic stem cell transplantation for sickle cell disease: The changing landscape

Hematology/ Oncology and Stem Cell Therapy

Volumn 10, Issue 4, 2017, Pages 259-266

  Kassim, Adetola A ^a   Sharma, Deva ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Chronic blood transfusion; Hematopoietic stem cell transplantation; Sickle cell anemia

Indexed keywords

CD45 ANTIGEN; DEFERASIROX; FERRITIN; HEMOGLOBIN S; HYDROXYUREA;

ACADEMIC ACHIEVEMENT; ACUTE CHEST SYNDROME; ADOLESCENT; ADULT; AVASCULAR NECROSIS; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; BONE MARROW TRANSPLANTATION; CASE REPORT; CEREBROVASCULAR ACCIDENT; CHOLELITHIASIS; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; LONG TERM CARE; LOW INCOME COUNTRY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; PAIN; PRIAPISM; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RISK FACTOR; SEPSIS; SIBLING; SICKLE CELL ANEMIA; TREATMENT OUTCOME; UNRELATED DONORS; VASO OCCLUSIVE PAIN EPISODE; ALLOGRAFT; DISEASE FREE SURVIVAL; DONOR SELECTION; GRAFT VERSUS HOST REACTION; INFECTION; INFECTION CONTROL; INFERTILITY; MORTALITY; PROCEDURES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

ALLOGRAFTS; ANEMIA, SICKLE CELL; DISEASE-FREE SURVIVAL; DONOR SELECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; INFECTION CONTROL; INFERTILITY; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 85026540280     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hemonc.2017.05.008     Document Type: Review

References (61)

1. Gardner, K., Douiri, A., Drasar, E., Allman, M., Mwirigi, A., Awogbade, M., et al. Survival in adults with sickle cell disease in a high-income setting. Blood 128 (2016), 1436–1438.
2. Gaston, M.H., Verter, J.I., Woods, G., Pegelow, C., Kelleher, J., Presbury, G., et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 314 (1986), 1593–1599.
3. Davies EG, Riddington C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease. Cochrane Database Sys Rrev; 2004. CD003885.
4. Yanni, E., Grosse, S.D., Yang, Q., Olney, R.S., Trends in pediatric sickle cell disease-related mortality in the United States, 1983–2002. J Pediatr 154 (2009), 541–545.
5. Vichinsky, E., Hurst, D., Earles, A., Kleman, K., Lubin, B., Newborn screening for sickle cell disease: effect on mortality. Pediatrics 81 (1988), 749–755.
6. Adams, R.J., Nichols, F.T., Figueroa, R., McKie, V., Lott, T., Transcranial Doppler correlation with cerebral angiography in sickle cell disease. Stroke 23 (1992), 1073–1077.
7. Adams, R.J., Snieder, H., McKie, V.C., Clair, B., Brambilla, D., Adams, R.J., et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Eng J Med 339 (1998), 5–11.
8. Bernaudin, F., Verlhac, S., Arnaud, C., Kamdem, A., Chevret, S., Hau, I., et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 117 (2011), 1130–1140 [quiz 1436].
9. DeBaun, M.R., Mae Gordon, M.P.H., McKinstry, R.C., Noetzel, M.J., White, D.A., Sarnaik, S.A., et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. New Engl J Med 371 (2014), 699–710.
10. Quinn, C.T., Rogers, Z.R., Buchanan, G.R., Survival of children with sickle cell disease. Blood 103 (2004), 4023–4027.
11. Telfer, P., Coen, P., Chakravorty, S., Wilkey, O., Evans, J., Newell, H., et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica 92 (2007), 905–912.
12. Quinn, C.T., Rogers, Z.R., McCavit, T.L., Buchanan, G.R., Improved survival of children and adolescents with sickle cell disease. Blood 115 (2010), 3447–3452.
13. Thomas, C., Lemerle, S., Bernaudin, F., Reinert, P., Sickle cell anemia: study of the pediatric mortality in Ile de France from 1985 to 1992. Archives Pediatrie Organe officiel Soc francaise pediatrie 3 (1996), 445–451 [in French].
14. Neonato, M.G., Guilloud-Bataille, M., Beauvais, P., Bégué P., Belloy, M., Benkerrou, M., et al. Acute clinical events in 299 homozygous sickle cell patients living in France. French study group on sickle cell disease. Euro J Haematol 65 (2000), 155–164.
15. Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H., et al. Mortality in sickle cell disease Life expectancy and risk factors for early death. New Engl J Med 330 (1994), 1639–1644.
16. Vichinsky, E.P., Neumayr, L.D., Earles, A.N., Williams, R., Lennette, E.T., Dean, D., et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. New Engl J Med 342 (2000), 1855–1865.
17. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. New Engl J Med 332 (1995), 1317–1322.
18. Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 115 (2010), 2354–2363.
19. Lobo, C.L., Pinto, J.F.C., Nascimento, E.M., Moura, P.G., Cardoso, G.P., Hankins, J.S., The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol 161 (2013), 852–860.
20. Le, P.Q., Gulbis, B., Dedeken, L., Dupont, S., Vanderfaeillie, A., Heijmans, C., et al. Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment. Pediatr Blood Cancer 62 (2015), 1956–1961.
21. Ohene-Frempong, K., Weiner, S.J., Sleeper, L.A., Miller, S.T., Embur, S., Moohr, J.W., et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 91 (1998), 288–294.
22. Anie, K.A., Egunjobi, F.E., Akinyanju, O.O., Psychosocial impact of sickle cell disorder: perspectives from a Nigerian setting. Global Health, 6, 2010, 2.
23. Schatz, J., Brown, R.T., Pascual, J.M., Hsu, L., DeBaun, M.R., Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology 56 (2001), 1109–1111.
24. Armstrong, F.D., Thompson, R.J. Jr., Wang, W., Zimmerman, R., Pegelow, C.H., Miller, S., et al. Cognitive functioning and brain magnetic resonance imaging in children with sickle Cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics 97 (1996), 864–870.
25. Powars, D.R., Elliott-Mills, D.D., Chan, L., Niland, J., Hiti, A.L., Opas, L.M., et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Int Med 115 (1991), 614–620.
26. McClellan, A.C., Luthi, J.C., Lynch, J.R., Soucie, J.M., Kulkarni, R., Guasch, A., et al. High 1 year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol 159 (2012), 360–367.
27. Bhalla, M., Abboud, M.R., McLoud, T.C., Shepard, J.A., Munden, M.M., Jackson, S.M., et al. Acute chest syndrome in sickle cell disease: CT evidence of microvascular occlusion. Radiology 187 (1993), 45–49.
28. Castro, O., Hoque, M., Brown, B.D., Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 101 (2003), 1257–1261.
29. Cheung, A.T., Chen, P.C., Larkin, E.C., Duong, P.L., Ramanujam, S., Tablin, F., et al. Microvascular abnormalities in sickle cell disease: a computer-assisted intravital microscopy study. Blood 99 (2002), 3999–4005.
30. van der Land, V., Heijboer, H., Fijnvandraat, K., Transfusions for silent cerebral infarcts in sickle cell anemia. New Engl J Med, 371, 2014, 1841.
31. Ware, R.E., Davis, B.R., Schultz, W.H., Brown, R.C., Aygun, B., Sarnaik, S., et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, noninferiority trial. Lancet 387 (2016), 661–670.
32. Ware, R.E., Helms, R.W., Investigators, S.W., Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood 119 (2012), 3925–3932.
33. Hulbert, M.L., McKinstry, R.C., Lacey, J.L., Moran, C.J., Panepinto, J.A., Thompson, A.A., et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 117 (2011), 772–779.
34. Aygun, B., Wruck, L.M., Schultz, W.H., Mueller, B.U., Brown, C., Luchtman-Jones, L., et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. Am J Hematol 87 (2012), 428–430.
35. Salaudeen, A.G., Musa, O.I., Awoyemi, A.O., Bolarinwa, A.O., Adegboye, A.O., Samuel, S.O., Community survey on blood donation practices in a northern state of Nigeria. J Prev Med Hyg 52 (2012), 21–25.
36. Jayaraman, S., Chalabi, Z., Perel, P., Guerriero, C., Roberts, I., The risk of transfusion-transmitted infections in subSaharan Africa. Transfusion 50 (2010), 433–442.
37. Lanzkron, S., Carroll, C.P., Haywood, C. Jr., Mortality rates and age at death from sickle cell disease: U.S., 1979–2005. Public Health Rep 128 (2013), 110–116.
38. Powars, D.R., Chan, L.S., Hiti, A., Ramicone, E., Johnson, C., Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine 84 (2005), 363–376.
39. Walters, M.C., De Castro, L.M., Sullivan, K.M., Krishnamurti, L., Kamani, N., Bredeson, C., et al. Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 22 (2016), 207–211.
40. Gluckman, E., Cappelli, B., Bernaudin, F., Labopin, M., Volt, F., Carreras, J., et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood, 2016, 10.1182/blood-2016-10-745711.
41. Walters, M.C., Hardy, K., Edwards, S., Adamkiewicz, T., Barkovich, J., Bernaudin, F., et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant 16 (2010), 263–272.
42. Vermylen, C., Cornu, G., Ferster, A., Brichard, B., Niane, J., Ferrant, A., et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 22 (1998), 1–6.
43. Matthes-Martin, S., Lawitschka, A., Fritsch, G., Lion, T., Grimm, B., Breuer, S., et al. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease. Eur J Haematol 90 (2013), 308–312.
44. Eggleston, B., Patience, M., Edwards, S., Adamkiewicz, T., Buchanan, G.R., Davies, S.C., et al. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. Br J Haematol 136 (2007), 673–676.
45. Walters, M.C., Patience, M., Leisenring, W., Rogers, Z.R., Aquino, V.M., Buchanan, G.R., et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 7 (2001), 665–673.
46. King, A.A., Kamani, N., Bunin, N., Sahdev, I., Brochstein, J., Hayashi, R.J., et al. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol 90 (2015), 1093–1098.
47. Hsieh, M.M., Kang, E.M., Fitzhugh, C.D., Link, B., Bolan, C.D., Kurlander, R., et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 361 (2009), 2309–2317.
48. Bernaudin, F., Socie, G., Kuentz, M., Chevret, S., Duval, M., Bertrand, Y., et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 110 (2007), 2749–2756.
49. O'Donnell, P.V., Luznik, L., Jones, R.J., Vogelsang, G.B., Leffell, M.S., Phelps, M., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 8 (2002), 377–386.
50. Gragert, L., Eapen, M., Williams, E., Freeman, J., Spellman, S., Baitty, R., et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 371 (2014), 339–348.
51. Shenoy, S., Eapen, M., Panepinto, J.A., Logan, B.R., Wu, J., Abraham, A., et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood 128 (2016), 2561–2567.
52. Ruggeri, A., Eapen, M., Scaravadou, A., Cairo, M.S., Bhatia, M., Kurtzberg, J., et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 17 (2011), 1375–1382.
53. Kamani, N.R., Walters, M.C., Carter, S., Aquino, V., Brochstein, J.A., Chaudhury, S., et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 18 (2012), 1265–1272.
54. Bolaños-Meade, J., et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 120 (2012), 4285–4291.
55. Dallas, M.H., Triplett, B., Shook, D.R., Hartford, C., Srinivasan, A., Laver, J., et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 19 (2013), 820–830.
56. Bhatia, M., Kolva, E., Cimini, L., Jin, Z., Satwani, P., Savone, M., et al. Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 21 (2015), 666–672.
57. Maheshwari, S., Kassim, A., Yeh, R.F., Domm, J., Calder, C., Evans, M., et al. Targeted Busulfan therapy with a steady-state concentration of 600–700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant. Bone Marrow Transp 49 (2014), 366–369.
58. Gluckman, E., Ruggeri, A., Rocha, V., Baudoux, E., Boo, M., Kurtzberg, J., et al. Family-directed umbilical cord blood banking. Haematologica 96 (2011), 1700–1707.
59. Fitzhugh, C.D., Abraham, A.A., Tisdale, J.F., Hsieh, M.M., Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions. Hematol Oncol Clin North Am 28 (2014), 1171–1185.
60. Fuchs, E.J., HLA-haploidentical blood or marrow transplantation with high-dose, posttransplantation cyclophosphamide. Bone Marrow Transplant 50:Suppl. 2 (2015), S31–6.
61. Angelucci, E., Matthew-Martin, S., Baronciani, D., Bernaudin, F., Bonanomi, S., Cappellini, M.D., et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica 99 (2014), 811–820.